Ella Jeffries / beckershospitalreview - Vinay Prasad, MD, the FDA’s top regulator of vaccines and cell and gene therapies, will step down at the end of April, an agency spokesperson confirmed to Becker’s. Dr. Prasad joined the agency in 2025 on a one-year sabbatical from the University of Calif…
#healthcare #publichealth #governmentpolicy #biotech #drugdevelopment #fda #vaccinesafety #infectiousdisease
Friday, March 6, 2026, 6:23 pm / permalink 20292 / 3 stories in 10 days
Emily Olsen / healthcaredive - The American Hospital Association argues new policies from Eli Lilly and Novo Nordisk requiring providers to submit more claims data on dispensed 340B drugs is onerous and unlawful.
#healthcare #pharmaceuticals #drugpricing #publichealth #governmentpolicy #hospitaloperations #healthcarefinance
Friday, March 6, 2026, 12:23 pm / permalink 20277 / 4 stories in 10 days
medicalxpress - A patient of mine, a veteran who had tried to quit smoking for over a decade, told me that after he started a GLP-1 drug for his diabetes, he lost interest in cigarettes. He didn't use a patch. He didn't set a quit date. He simply lost interest. It happen…
#obesity #healthcare #pharmaceuticals #elililly #novonordisk #weightloss #publichealth #drugdevelopment #behavioralhealth
Friday, March 6, 2026, 12:23 pm / permalink 20276 / 10 stories in 10 days
sciencedaily - Researchers created an AI-driven liquid biopsy that scans patterns in fragments of DNA circulating in the blood. The system detected early liver fibrosis and cirrhosis—conditions that often go unnoticed until serious damage occurs. By analyzing genome-wid…
#healthcare #publichealth #biotech #digitalhealth #medicaldevices #healthcarefinance
Friday, March 6, 2026, 1:22 am / permalink 20251 / 7 stories in 10 days
HIMSS 2026 pushes real‑time data, cloud and interoperability playbook 14 stories in 16.5 hours
Neoadjuvant GOLP improves event‑free survival in high‑risk intrahepatic cholangiocarcinoma 3 stories in 17.5 hours
Vitamin D trial shows reduced long‑COVID risk but no severity benefit 2 stories in 19.5 hours
Atezolizumab added to chemoradiation fails to improve limited‑stage SCLC survival 4 stories in 20.5 hours
FDA approves leucovorin for rare folate disorder despite autism hype 4 stories in 32.5 hours
HORMAD1 emerges as a potential target in triple‑negative breast cancer 4 stories in 45.5 hours
Alfasigma pays $300M to GSK for linerixibat rights, expanding liver-disease portfolio 2 stories in 48.5 hours
Roche’s hoped‑for breast cancer pill fails crucial first‑line trial 5 stories in 49.5 hours
Novo Nordisk and Hims bury the hatchet and carve a deal 3 stories in 54.5 hours
AI improves UK breast-screening detection by about 10% 5 stories in 54.5 hours
NorthFeed Inc.
Disclaimer: The information provided on this website is intended for general informational purposes only. While we strive for accuracy, we do not guarantee the completeness or reliability of the content. Users are encouraged to verify all details independently. We accept no liability for errors, omissions, or any decisions made based on this information.
Bluesky: